AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6

Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6

LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, August 6, 2020.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to: .

To access the live and subsequent replay of this webcast that will be live for two weeks and view the accompanying slide presentation, please register .

Contact:

Lucinda Crabtree, PhD

Vice President, Investor Relations and Corporate Communications

+44 (0) 7587 372 619 

Julia Wilson

+44 (0) 7818 430877 

 

Susan A. Noonan

S.A. Noonan Communications

 

EN
30/07/2020

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE ...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting an immune resetNine patients were evaluable for safety, no ICANS or high-grade CRS were observed LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NE...

December 8, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B...

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel’s adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as pote...

December 8, 2025 1 EN
Guy Sips ... (+3)
  • Guy Sips
  • Jacob Mekhael
  • Wim Lewi
JEN JENSEN-GROUP
MONT MONTEA SCA
AUTL AUTOLUS THERAPEUTICS ADS
BTLS BIOTALYS NV
12/02/25 December 2, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company’s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus’ Board. “Autolus has entered a new pha...

December 1, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus NICE recommends Aucatzyl for r/r adult B-ALL in England and Wa...

Autolus announced that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending Aucatzyl (obe-cel, CD19 CAR-T) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (=26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). Aucatzyl will be available through routine commissioning by the NHS, and Autolus intends to launch the product in England and Wales immi...

AUTL AUTOLUS THERAPEUTICS ADS
11/26/25 November 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch